Israeli pharmaceutical company Kamada has announced that it has received FDA approval for a phase II and III clinical trial of AATD-IH, an inhalable version of its AAT drug, which is designed to treat congenital emphysema.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments